Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1380P - High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer

Date

10 Sep 2022

Session

Poster session 10

Topics

Clinical Research;  Cancer Biology;  Translational Research;  Targeted Therapy;  Molecular Oncology;  Genetic and Genomic Testing, Counseling;  Prostate Cancer

Presenters

Naoual MENSSOURI

Citation

Annals of Oncology (2022) 33 (suppl_7): S616-S652. 10.1016/annonc/annonc1070

Authors

N. MENSSOURI1, Y. Wesseling-Rozendaal2, L. Poiraudeau1, C. Helissey3, L. Bigot4, J. SABIO5, T. Ibrahim6, C. Nicotra7, L. Tselikas8, E. COLOMBA9, P. Lavaud10, B. Besse11, J. Scoazec12, E. den Biezen13, S. Neerken13, K. Fizazi14, D. GAUTHERET15, P. van de Wiel13, Y. Loriot14

Author affiliations

  • 1 U981, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Molecular Pathway Dx, InnoSIGN B.V, 5656 AE - Eindhoven/NL
  • 3 Clinical Research Unit, Bégin Military Teaching Hospital, 94160 - Saint-Mandé/FR
  • 4 U981, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 5 U981, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 6 Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 7 Ditep, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 8 Interventional Radiology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 9 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 10 Medical Oncology Departement, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 11 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 12 Pathology Dept., Institut Gustave Roussy, 94805 - Villejuif/FR
  • 13 Molecular Pathway Dx, Philips Healthcare, 5621 JG - Eindhoven/NL
  • 14 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 15 Ihu-prism, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
More

Abstract 1380P

Background

The androgen-receptor pathway inhibitors (ARPI) are standard treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the mechanisms of both primary and acquired resistance remain largely unknown.

Methods

In a prospective precision oncology trial, MATCH-R (NCT02517892), 55 mCRPC patients were included among whom 45 underwent whole exome sequencing (WES) and 52 RNA-sequencing (RNA-seq) of tumor tissue biopsies before starting ARPI. 16 patients who initially responded to the treatment underwent a second biopsy at resistance (WES=14, RNA-seq=14). Functional activity of signal transduction pathways was determined from RNA-seq data using OncoSIGNal (InnoSIGN, The Netherlands) and by gene set enrichment analysis. Associations of genomic and transcriptomic alterations with resistance were determined using Wilcoxon and Fisher's exact tests.

Results

22/55 patients had primary resistance. No genomic alteration detected on WES analysis was significantly associated with primary resistance. Analysis of sequential biopsies suggested that mCRPC follows mainly a parallel evolution model. At time of acquired resistance, most tumors have acquired new drivers affecting AR pathway (e.g, AR, NCOR1/2) or lineage switching (e.g, RB1, PTEN, TP53). AR gene alterations and AR expression were similar between responders and non-responders. Transcriptional analysis has demonstrated that multiple specific gene sets - including those linked to low AR-transcriptional-activity, stemness program, RB loss and homologous repair deficiency – were activated in both primary and acquired resistance. OncoSIGNal analysis has revealed that high HH and low AR pathways activity were associated with resistance to ARPI.

Conclusions

Multiple transcriptional programs already activated in pre-treated samples were associated with resistance to ARPI. Clonal evolution analysis along with RNA-seq data point to the role of genomic instability and lineage switching in driving acquired resistance. Specifically, the activity of the HH pathway may play a critical role in resistance to ARPI.

Clinical trial identification

NCT02517892.

Editorial acknowledgement

Legal entity responsible for the study

Institut Gustave Roussy.

Funding

Sanofi and Janssen.

Disclosure

C. Helissey: Financial Interests, Personal, Invited Speaker: Janssens, roche, Astellas, AstraZeneca, Sanofi; Non-Financial Interests, Principal Investigator: Janssen, Sanofi, roche, Astellas. P. Lavaud: Financial Interests, Personal, Advisory Role: Astellas, AstraZeneca, Sanofi, Janssen; Financial Interests, Personal, Other, Travel accommodation: Ipsen, Janssen, Astellas, Pfizer. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Chugai pharmaceutical, EISAI, Genzyme Corporation, Inivata, Ipsen, Turning Point Therapeutics. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion. Y. Loriot: Financial Interests, Personal, Advisory Board: Merck KGaA, Pfizer, Gilead, Seattle Genetics, Taiho; Financial Interests, Personal, Other, Lectures, Advisory Boards: MSD, AstraZeneca, Astellas, Janssen; Financial Interests, Personal, Other, Lectures, Advisory Boards: Roche, BMS; Financial Interests, Institutional, Research Grant: Janssen, Sanofi, MSD, Roche, Celsius; Financial Interests, Institutional, Invited Speaker: Janssen, Pfizer, MSD, Exelexis, AstraZeneca, Pfizer, Merck KGaA, BMS, Astellas, Gilead, Incyte; Financial Interests, Invited Speaker: MSD, Astellas, Gilead/Immunomedics, Taiho; Financial Interests, Personal, Invited Speaker: Basilea; Non-Financial Interests, Member: ESMO, ASCO, AACR; Non-Financial Interests, Other, Scientific Committee: ARC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.